Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is making significant strides in RNA interference (RNAi) therapeutics, focusing on rare diseases and cardiovascular conditions.The company's revenue boost is attributed to its diversified drug portfolio, including Amvuttra, which has seen approval in the U.S. and EU.Despite challenges such as a negative price-to-earnings (P/E) ratio of -185.46 and a high debt-to-equity ratio of 5.18, Alnylam shows strong financial performance with a current ratio of 2.80.Alnylam P ...